Small Cell Lung Cancer

Gene G. Finley, MD, discusses the challenges that community oncologists are facing with small cell lung cancer treatment.

Gene G. Finley, MD, discusses how he envisions the treatment landscape of small cell lung cancer may evolve over the next 5-10 years.

JBI-802, which is being evaluated in a phase 1/2 trial, received an orphan drug designation from the FDA for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.

Patients with small cell lung cancer will receive diagnostic and post-progression tumor tissue profiling, plasma ctDNA biomarker profiling, standard of care therapy, and disease surveillance in the Sculptor study.

Kartik Konduri, MD discussed treatment options for extensive-stage small cell lung cancer during a live virtual event.

Gene G. Finley, MD, discusses some of the challenges seen when treating patients with small cell lung cancer.

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

Gene G. Finley, MD, discusses the potential use of molecular testing to improve outcomes for patients with relapsed small cell lung cancer.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.

Gene G. Finley, MD, explains the use of conventional chemotherapy in the small cell lung cancer space.

In an interview with Targeted Oncology, Gene G. Finley discussed the many wins and losses experts have seen in the small cell lung cancer space. He also explained his hopes for the future of this space.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.

Gene G. Finley, MD, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.

During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed the data supporting the use of immunotherapy for patients with extensive-stage small cell lung cancer.

Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.

At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.

Following positive phase 1/2 results of DS-7300 use in patients with extensive-stage small cell lung cancer, a phase 2 study has dosed its first patient with the experimental agent.